Genetically modified muscle cells which express neurotrophic factors
US10744162B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Mar 14, 2019 |
| Grant date | Aug 18, 2020 |
| Priority date | — |
| Expiry date | Mar 14, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2510/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An isolated muscle progenitor cell being MyoD positive, CD34 negative and CD45 negative is disclosed. The muscle progenitor cell is genetically modified to express at least one neurotrophic factor. In addition, cell populations are disclosed, comprising at least four subpopulations of muscle cells each being genetically modified to express a different neurotrophic factor, wherein said neurotrophic factor is selected from the group consisting of glial derived neurotrophic factor (GDNF), insulin growth factor (IGF-1), vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor (BDNF). Uses of the cell populations are also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.